ATE529105T1 - Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung - Google Patents
Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankungInfo
- Publication number
- ATE529105T1 ATE529105T1 AT08768441T AT08768441T ATE529105T1 AT E529105 T1 ATE529105 T1 AT E529105T1 AT 08768441 T AT08768441 T AT 08768441T AT 08768441 T AT08768441 T AT 08768441T AT E529105 T1 ATE529105 T1 AT E529105T1
- Authority
- AT
- Austria
- Prior art keywords
- lipoic acid
- inflammatory bowel
- compositions
- subject invention
- administration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title abstract 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 2
- 235000019136 lipoic acid Nutrition 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229960002663 thioctic acid Drugs 0.000 abstract 3
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 2
- 241000792859 Enema Species 0.000 abstract 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000007920 enema Substances 0.000 abstract 2
- 229940095399 enema Drugs 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 230000036542 oxidative stress Effects 0.000 abstract 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 abstract 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 229930182816 L-glutamine Natural products 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004963 mesalazine Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Dental Preparations (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93450507P | 2007-06-13 | 2007-06-13 | |
| US6374508P | 2008-02-06 | 2008-02-06 | |
| PCT/US2008/007401 WO2008156671A2 (en) | 2007-06-13 | 2008-06-13 | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE529105T1 true ATE529105T1 (de) | 2011-11-15 |
Family
ID=40156844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08768441T ATE529105T1 (de) | 2007-06-13 | 2008-06-13 | Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8476233B2 (de) |
| EP (2) | EP2162125B1 (de) |
| JP (1) | JP2010529197A (de) |
| KR (1) | KR20100038098A (de) |
| CN (1) | CN101707877B (de) |
| AT (1) | ATE529105T1 (de) |
| AU (1) | AU2008266996A1 (de) |
| BR (1) | BRPI0812729A2 (de) |
| CA (1) | CA2691132C (de) |
| IL (1) | IL202685A0 (de) |
| MX (1) | MX2009013683A (de) |
| NZ (1) | NZ581710A (de) |
| WO (1) | WO2008156671A2 (de) |
| ZA (1) | ZA200908828B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| US20100112088A1 (en) * | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
| AU2013220464A1 (en) * | 2012-02-13 | 2014-09-04 | Cosmo Technologies Limited | Method for treating intestinal diseases presenting at least one inflammatory component |
| JP6566638B2 (ja) * | 2012-03-07 | 2019-08-28 | サンタラス， インコーポレイテッドＳａｎｔａｒｕｓ，Ｉｎｃ． | メサラミンの放出制御固形製剤 |
| JP6509112B2 (ja) * | 2012-07-03 | 2019-05-08 | プラブダ，ジェイ | オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 |
| CA2891090A1 (en) * | 2012-11-09 | 2014-05-15 | Scidose, Llc | Enema composition for treatment of ulcerative colitis having long term stability |
| CN103622974B (zh) * | 2013-12-05 | 2016-04-20 | 武汉武药科技有限公司 | 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法 |
| EP3251676A4 (de) | 2015-01-26 | 2018-09-19 | Dr. Falk Pharma Gmbh | Klistier zur rektalen anwendung |
| EP3115037B1 (de) * | 2015-07-08 | 2018-08-15 | Dr. Falk Pharma Gmbh | Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms |
| JP6878453B2 (ja) * | 2015-11-27 | 2021-05-26 | ビルベヘール・ベー・フェー | 炎症性疾患に使用するための酪酸塩 |
| EP3516389A4 (de) * | 2016-09-26 | 2020-09-02 | Precision Medicine Holdings Pty Ltd | Diagnose, prognose und behandlung von schizophrenie und schizoaffektiver psychose |
| WO2018122086A1 (en) * | 2016-12-28 | 2018-07-05 | Dr. Falk Pharma Gmbh | Enema for rectal application |
| CN108034631A (zh) * | 2017-12-04 | 2018-05-15 | 武汉轻工大学 | 一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法 |
| JP2019113375A (ja) * | 2017-12-22 | 2019-07-11 | サッポロホールディングス株式会社 | 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法 |
| KR102597785B1 (ko) * | 2018-01-18 | 2023-11-02 | 각고호우징 게이오기주크 | 궤양성 대장염 치료 캡슐제 |
| WO2024026200A1 (en) * | 2022-07-27 | 2024-02-01 | Redox Bioscience LLC | Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211777A (en) * | 1977-11-25 | 1980-07-08 | Fisons Limited | Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid |
| WO1981002671A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
| US4657900A (en) * | 1983-09-27 | 1987-04-14 | Rowell Laboratories | Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method |
| EP0382066A3 (de) * | 1989-02-09 | 1992-01-08 | ASTA Medica Aktiengesellschaft | Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum |
| GB8909559D0 (en) * | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
| US5378470A (en) * | 1989-07-25 | 1995-01-03 | Henning Berlin Gmbh | Rectally administered pharmaceutical preparation |
| DK0427247T3 (da) * | 1989-11-09 | 1998-09-28 | Asta Medica Ag | Lægemiddel indeholdende R-alpha- lipoinsyre eller S-alphalipoinsyre som aktiv bestanddel |
| DE4218572A1 (de) | 1992-06-05 | 1993-12-09 | Asta Medica Ag | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E |
| US5569670A (en) * | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| US6444221B1 (en) * | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US8178516B2 (en) * | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| JP2917799B2 (ja) * | 1994-03-11 | 1999-07-12 | 田辺製薬株式会社 | 消化管内適所放出型製剤 |
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| DE19509806A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Lagerstabile Arzneiformen |
| US5817630A (en) * | 1997-03-18 | 1998-10-06 | Austin Nutriceutical Corporation | Glutathione antioxidant eye drops |
| US6197749B1 (en) * | 1997-10-29 | 2001-03-06 | Ajinomoto Co., Inc. | Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes |
| US6262019B1 (en) * | 1998-04-30 | 2001-07-17 | Vit-Immune, L. C. | Method of treatment of glutathione deficient mammals |
| CA2274943A1 (en) * | 1998-06-17 | 1999-12-17 | Stephen L. Wolman | Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof |
| AR042572A1 (es) | 1999-04-02 | 2005-06-29 | Sod Conseils Rech Applic | Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos |
| US6664287B2 (en) * | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
| EP1172110A3 (de) * | 2000-07-07 | 2003-09-17 | Basf Aktiengesellschaft | Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen |
| BR0209474A (pt) | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
| US20030235571A1 (en) * | 2002-06-19 | 2003-12-25 | Gabriel Gojon-Romanillos | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| WO2004024868A2 (en) * | 2002-09-10 | 2004-03-25 | National Jewish Medical And Research Center | Product and process for liquefaction of mucus or sputum |
| US7157444B2 (en) * | 2002-12-21 | 2007-01-02 | Deanna Jean Nelson | Aminosalicylate derivatives for treatment of inflammatory bowel disease |
| DE10305661A1 (de) | 2003-02-12 | 2004-08-26 | Degussa Ag | Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung |
| EP1603556A2 (de) * | 2003-03-06 | 2005-12-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Multifunktionelle verbindungen enthaltend gruppen zur nachahmung von sod zur behandlung von chronisch-entzündlichen darmerkrankungen |
| US20100112088A1 (en) * | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
-
2008
- 2008-06-13 WO PCT/US2008/007401 patent/WO2008156671A2/en active Application Filing
- 2008-06-13 AT AT08768441T patent/ATE529105T1/de not_active IP Right Cessation
- 2008-06-13 EP EP08768441A patent/EP2162125B1/de not_active Not-in-force
- 2008-06-13 EP EP11179459A patent/EP2392321A1/de not_active Withdrawn
- 2008-06-13 MX MX2009013683A patent/MX2009013683A/es active IP Right Grant
- 2008-06-13 KR KR1020107000650A patent/KR20100038098A/ko not_active Application Discontinuation
- 2008-06-13 CA CA2691132A patent/CA2691132C/en not_active Expired - Fee Related
- 2008-06-13 JP JP2010512198A patent/JP2010529197A/ja not_active Abandoned
- 2008-06-13 BR BRPI0812729-8A patent/BRPI0812729A2/pt not_active IP Right Cessation
- 2008-06-13 NZ NZ581710A patent/NZ581710A/en not_active IP Right Cessation
- 2008-06-13 CN CN2008800201249A patent/CN101707877B/zh not_active Expired - Fee Related
- 2008-06-13 US US12/664,237 patent/US8476233B2/en not_active Expired - Fee Related
- 2008-06-13 AU AU2008266996A patent/AU2008266996A1/en not_active Abandoned
-
2009
- 2009-12-10 IL IL202685A patent/IL202685A0/en unknown
- 2009-12-10 ZA ZA2009/08828A patent/ZA200908828B/en unknown
-
2013
- 2013-06-28 US US13/930,838 patent/US20130344184A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101707877A (zh) | 2010-05-12 |
| CA2691132C (en) | 2016-01-12 |
| NZ581710A (en) | 2012-02-24 |
| BRPI0812729A2 (pt) | 2019-02-12 |
| US20130344184A1 (en) | 2013-12-26 |
| ZA200908828B (en) | 2010-12-29 |
| CA2691132A1 (en) | 2008-12-24 |
| AU2008266996A1 (en) | 2008-12-24 |
| US8476233B2 (en) | 2013-07-02 |
| WO2008156671A3 (en) | 2009-03-12 |
| EP2162125A4 (de) | 2010-08-25 |
| EP2162125A2 (de) | 2010-03-17 |
| CN101707877B (zh) | 2013-01-09 |
| EP2162125B1 (de) | 2011-10-19 |
| KR20100038098A (ko) | 2010-04-12 |
| JP2010529197A (ja) | 2010-08-26 |
| WO2008156671A2 (en) | 2008-12-24 |
| IL202685A0 (en) | 2010-06-30 |
| EP2392321A1 (de) | 2011-12-07 |
| MX2009013683A (es) | 2010-04-07 |
| US20100184728A1 (en) | 2010-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE529105T1 (de) | Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung | |
| Martinez-Arguelles et al. | In utero exposure to di-(2-ethylhexyl) phthalate decreases mineralocorticoid receptor expression in the adult testis | |
| Morrissey et al. | Enduring deficits in contextual and auditory fear conditioning after adolescent, not adult, social instability stress in male rats | |
| Wilson et al. | Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. | |
| Martinez–Arguelles et al. | Maternal in utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate affects the blood pressure of adult male offspring | |
| WO2008085484A3 (en) | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid | |
| Sarkar et al. | Probiotics protect against gut dysbiosis associated decline in learning and memory | |
| AR079479A1 (es) | Composiciones oftalmicas no irritantes de povidona iodada | |
| WO2005072113A3 (en) | Compositions and methods of treatment for inflammatory diseases | |
| Hypomineralization | Molar incisor hypomineralization | |
| AR058749A1 (es) | Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento | |
| BRPI0512535A (pt) | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações | |
| EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| AR066292A1 (es) | Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario | |
| WO2008137762A3 (en) | Methods of diagnosis and treatment of crohn's disease | |
| DE602004028731D1 (de) | Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid | |
| UA110463C2 (ru) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я | |
| Friedman et al. | Cleft palate, retrognathia and congenital heart disease in velo-cardio-facial syndrome: a phenotype correlation study | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| ZA202002103B (en) | Compounds as mpges-1 inhibitors | |
| ATE549923T1 (de) | Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| Wysokinski et al. | The A Allele of the-576G> A polymorphism of the transferrin gene is associated with the increased risk of age-related macular degeneration in smokers | |
| JP2015523364A5 (de) | ||
| BR112017025392A2 (pt) | composições vaginais dependentes de ph e métodos de tratamento de distúrbios vaginais | |
| Degen et al. | The development of various somatic markers is retarded in an animal model for schizophrenia, namely apomorphine-susceptible rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |